SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

US FDA Approves Biocon Biosimilar to Cancer Drug Perjeta

Biocon said Pebrilzo is its fifth US FDA-approved oncology biosimilar.

BIOCON

Shares of Biocon gained on Monday, November 16, after the company secured US Food and Drug Administration (FDA) approval for Pebrilzo, a biosimilar to the cancer drug Perjeta.The approval was its fifth USFDA-approved oncology biosimilar, the company said in a regulatory filing on Monday."The US FDA…

Related stories